DDX53 and glioma: Subsequently, the viral sensitizing potential of DMF in impacting HSV.n212 viral titers was evaluated in several cancer subtypes including breast (murine 4T1), colon (murine CT26.wt, human HT29), glioma (murine CT2A), sarcoma (murine S180), renal (human 786-0) and melanoma (patient derived OHRI-13) where we observed a significant increase compared to HSV.n212 alone (Figures 1B, C).